Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 2
Submit an article Journal homepage
227
Views
7
CrossRef citations to date
0
Altmetric
Letters to the Editor

Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained

Thomas E. WitzigDivision of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA
,
Tammy L. Price-TroskaDivision of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA
,
Mary J. StensonDivision of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA
&
Mamta GuptaDivision of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USACorrespondence[email protected]
Pages 397-399 | Received 20 Jun 2012, Accepted 26 Jun 2012, Published online: 17 Aug 2012

References

  • Ding BB, Yu JJ, Yu RY, . Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008;111:1515–1523.
  • Lam LT, Wright G, Davis RE, . Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008;111:3701–3713.
  • Gupta M, Maurer M, Wellik L. STAT3 tyrosine phosphorylation is frequent in diffuse large B cell lymphoma and is independent of molecular subtype: Implications for biomarker. Proceedings of the 103rd Annual meeting of the AACR: 2012 Mar 31-Apr 4; Chicago, IL; Cancer Res 2012; 72.
  • Gupta M, Han JJ, Stenson M, . Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 2012;119:2844–2853.
  • Malumbres M, Barbacid M.RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459–465.
  • Libra M, Malaponte G, Navolanic PM, . Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 2005;4:1382–1384.
  • James C, Ugo V, Le Couedic JP, . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–1148.
  • Levine RL, Wadleigh M, Cools J, . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387–397.
  • Steensma DP, McClure RF, Karp JE, . JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006;20:971–978.
  • Levine RL, Loriaux M, Huntly BJ, . The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005;106:3377–3379.
  • Melzner I, Weniger MA, Menz CK, . Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia 2006;20: 157–158.
  • Chim CS, Wong KY, Loong F, . SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia 2004;18:356–358.
  • Kube D, Holtick U, Vockerodt M, . STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001;98:762–770.
  • Ghoreschi K, Laurence A, O’Shea JJ.Janus kinases in immune cell signaling. Immunol Rev 2009;228:273–287.
  • Elliott NE, Cleveland SM, Grann V, . FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011;118:3911–3921.
  • Lohr JG, Stojanov P, Lawrence MS, . Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012;109:3879–3884.
  • Verstovsek S, Kantarjian H, Mesa RA, . Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117–1127.
  • Pardanani A, Gotlib JR, Jamieson C, . Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789–796.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.